Inhibrx Biosciences (INBX) Common Equity: 2023-2025
Historic Common Equity for Inhibrx Biosciences (INBX) over the last 2 years, with Sep 2025 value amounting to $36.8 million.
- Inhibrx Biosciences' Common Equity fell 79.36% to $36.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.8 million, marking a year-over-year decrease of 79.36%. This contributed to the annual value of $133.6 million for FY2024, which is 207.07% up from last year.
- According to the latest figures from Q3 2025, Inhibrx Biosciences' Common Equity is $36.8 million, which was down 46.28% from $68.6 million recorded in Q2 2025.
- Inhibrx Biosciences' Common Equity's 5-year high stood at $219.4 million during Q2 2024, with a 5-year trough of $36.8 million in Q3 2025.
- Moreover, its 3-year median value for Common Equity was $94.4 million (2025), whereas its average is $110.7 million.
- Its Common Equity has fluctuated over the past 5 years, first skyrocketed by 207.07% in 2024, then crashed by 79.36% in 2025.
- Quarterly analysis of 3 years shows Inhibrx Biosciences' Common Equity stood at $43.5 million in 2023, then surged by 207.07% to $133.6 million in 2024, then crashed by 79.36% to $36.8 million in 2025.
- Its last three reported values are $36.8 million in Q3 2025, $68.6 million for Q2 2025, and $94.4 million during Q1 2025.